SCHEMBL104063

SCHEMBL104063

O=C(CCN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1)c1ccc2[nH]c(=O)oc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 4/20 0.62
KCNH2 Q12809 1/20 0.62
DRD3 P35462 4/20 0.55
HRH4 Q9H3N8 5/20 0.55
HRH3 Q9Y5N1 2/20 0.55
HRH1 P35367 1/20 0.55
DRD2 P14416 2/20 0.54
KMT2A Q03164 3/20 0.51
MEN1 O00255 1/20 0.51
GRIN2D O15399 1/20 0.51
GRIN3B O60391 1/20 0.51
GRIN1 Q05586 1/20 0.51
GRIN2A Q12879 1/20 0.51
GRIN2B Q13224 1/20 0.51
GRIN2C Q14957 1/20 0.51
GRIN3A Q8TCU5 1/20 0.51
POLB P06746 1/20 0.50
AKR1C3 P42330 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL106393 0.89 AKR1C3 (0.62) ENPP2KCNH2DRD3HRH4DRD2
SCHEMBL105126 0.84 ENPP2 (0.59) ENPP2KCNH2DRD3KMT2AMEN1
SCHEMBL106327 0.83 ENPP2 (0.59) ENPP2KCNH2KMT2AMEN1GRIN2D
SCHEMBL105499 0.81 ENPP2 (0.68) ENPP2KCNH2KMT2AGRIN2DGRIN3B
SCHEMBL107137 0.81 ENPP2 (0.63) ENPP2KCNH2KMT2AMEN1GRIN2D
SCHEMBL3041478 0.81 ENPP2 (0.72) ENPP2KCNH2KMT2AGRIN2DGRIN3B
SCHEMBL103855 0.80 ENPP2 (0.64) ENPP2KCNH2DRD3HRH1KMT2A
SCHEMBL105939 0.80 ENPP2 (0.71) ENPP2KCNH2GRIN2DGRIN3BGRIN1
SCHEMBL108402 0.80 ENPP2 (0.61) ENPP2KCNH2GRIN2DGRIN3BGRIN1
SCHEMBL104959 0.79 ENPP2 (0.57) ENPP2KCNH2GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791111-B2 Piperidine and piperazine derivatives MERCK PATENT GMBH (DE) 2014-07-29 US claimed
EP-2426106-B1 Piperidine and Piperazine derivatives for the treatment of tumours MERCK PATENT GMBH (DE) 2013-07-31 EP claimed
EP-2426106-A1 Piperidine and Piperazine derivatives for the treatment of tumours Merck Patent GmbH (DE) 2012-03-07 EP claimed
US-20100222341-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HARTUNG (DE) 2010-09-02 US claimed
EP-2193118-A2 PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS Merck Patent GmbH (DE) 2010-06-09 EP claimed
WO-2009046841-A2 PIPERIDINE AND PIPERAZINE DERIVATIVES FOR TREATING TUMOURS MERCK PATENT GMBH (DE) 2009-04-16 WO claimed
EP-2426106-B1 Piperidine and Piperazine derivatives for the treatment of tumours MERCK PATENT GMBH (DE) 2013-07-31 EP disclosed
EP-2426106-A1 Piperidine and Piperazine derivatives for the treatment of tumours Merck Patent GmbH (DE) 2012-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222341-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES CCND2, CCND1, TPD52L2 ENPP2 3706/4885KCNH2 66/4885DRD3 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.